Status:

WITHDRAWN

Intracoronary Bradykinin Mediated t-PA Release in Heart Transplant Recipients

Lead Sponsor:

Vanderbilt University

Conditions:

Heart Transplantation

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

Heart transplant recipients do not have nerves to their hearts. This protocol tests the hypothesis that bradykinin mediated t-PA release in the coronary arteries will be reduced in heart transplant re...

Eligibility Criteria

Inclusion

  • Inclusion criteria:
  • Heart transplant recipients undergoing annual cardiac catheterization who have participated our protocol: Characterization of brachial arterial t-PA release, vasodilator function, and vascular compliance and correlation with fibrinolytic balance, oxidative stress, and inflammation measures in heart transplant recipients (SCCOR Project 1, Aim 3C). (IRB # 070517)
  • 25 Subjects will have transplant vasculopathy and 25 subjects will be free of transplant vasculopathy, as documented in previous angiograms.
  • Otherwise healthy
  • Exclusion criteria:
  • PVC \< 30
  • Hypertensive subjects on ACE inhibitors
  • Pregnant or nursing mothers
  • Diabetic with HbA1C \> 7.5 or stigmata of end organ damage (neuropathy, retinopathy, nephropathy, cardiomyopathy)
  • Cholesterol \> 30 mg/dL above NCEP accepted level based on cardiac risk.
  • Triglycerides \> 200
  • Previously diagnosed obstructive coronary artery disease
  • Renal insufficiency (Creatinine ≥ 1.5 mg/dl)
  • History of cerebrovascular disease
  • Any chronic inflammatory disease (rheumatologic, inflammatory bowel disease, etc)
  • Uncontrolled Stage 2 Hypertension (160/100 mmHg), or end organ damage due to hypertension (left ventricular hypertrophy, atrial fibrillation, hematuria, renal insufficiency, prior cerebrovascular disease).
  • Angiotensin converting enzyme inhibitor use
  • Coagulopathy (INR ≥ 1.5, PTT ≥ 150% of control)
  • Peripheral Vascular Disease
  • Other chronic medical illnesses at the discretion of the investigators
  • Healthy controls are being enrolled in SCCOR Project 1, Aims 3A and 3B (IRB# 030473 and 061160) and will not be participating under this IRB number.

Exclusion

    Key Trial Info

    Start Date :

    October 1 2008

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    May 1 2011

    Estimated Enrollment :

    Patients enrolled

    Trial Details

    Trial ID

    NCT00780377

    Start Date

    October 1 2008

    End Date

    May 1 2011

    Last Update

    March 20 2017

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Vanderbilt University Medical Center

    Nashville, Tennessee, United States, 37232